細胞治療技術市場：製品、治療タイプ、製造プロセス、送達方法、用途、エンドユーザー別-2025-2030年の世界予測

細胞治療技術市場は、2024年には46億6,000万米ドルとなり、2025年には52億9,000万米ドル、CAGR14.05％で成長し、2030年には102億5,000万米ドルに達すると予測されています。

細胞治療技術の分野は、再生医療や腫瘍学において画期的な治療を可能にし、現代の医療技術革新の要として急速に台頭してきました。この市場は、画期的な科学的発見の流入と、従来の治療アプローチの限界を再定義する投資の急増を目の当たりにしています。業界利害関係者がますます複雑化する規制環境に対応し、高まる患者の期待に対処する中で、確かな市場洞察の必要性はかつてないほど高まっています。

最近の実験技術、製造プロセス、品質管理手法の進歩は、新規の細胞ベースの治療法の商業化への道を開いています。官民両セクターの投資に後押しされ、エコシステムは猛烈なスピードで進化しています。本分析概要では、市場セグメンテーション、地域動向、主要な業界プレイヤーといった重要な要素を詳細に検証しながら、細胞治療技術の革新的な精神を要約しています。以下の考察は、意思決定者がこのダイナミックな状況における動向、機会、課題をバランスよく、事実に基づいて理解することを目的としています。

細胞治療技術の展望を形成する変革的シフト

近年、科学的イノベーション、戦略的投資、規制状況の進化が相まって、細胞治療技術の状況は大きく変化しています。バイオプロセスと自動化における新たなテクノロジーは製造に革命をもたらし、効率性と拡張性の向上につながりました。さらに、デジタルの進歩は、データ主導の知見と従来の研究室ベースのアプローチを統合する上で重要な役割を果たすようになり、それによってより精密な治療が可能になり、厳格な品質管理が保証されるようになっています。

市場力学もまた、学際的な共同研究によって再構築されており、学術機関とバイオ医薬品企業がリソースと専門知識を出し合って、画期的な新薬を迅速に開発できるようになっています。各地域の規制当局は、患者の安全を守るだけでなく、市場投入を加速させる先進的な政策を導入しています。こうした進歩的なシフトに加え、個別化された低侵襲性の治療に対する消費者の需要が高まっています。これらの要因が相まって、この業界が実験的治療から、広く利用可能で効果の高い治療ソリューションへと移行しつつあることを示唆しています。技術革新、規制、市場の需要の相互作用は、創造的破壊の状況と変革の可能性を提供し続けています。

細胞治療技術市場の主要セグメンテーション洞察

市場を詳細に調査すると、細胞治療技術の多様な分類に関する洞察を提供する重要なセグメンテーションの次元が明らかになります。提供物に基づいて分析すると、市場は消耗品、機器、ソフトウェアとサービスに分類され、機器自体はバイオリアクターと細胞分析装置に分けられ、ソフトウェアとサービスはさらにデータ管理と品質管理に分かれます。この階層的なセグメンテーションは、サプライチェーンの多面的な性質と、デジタルソリューションと従来のハードウェアの統合が市場の発展を促進していることを強調しています。

さらに治療法のタイプ別に分類すると、同種細胞療法、自家細胞療法、遺伝子組み換え細胞療法があります。詳細な分析によれば、同種細胞療法は樹状細胞、人工多能性幹細胞、ナチュラルキラー細胞に枝分かれし、自己細胞療法は造血幹細胞、間葉系幹細胞、T細胞を対象としています。遺伝子組み換え細胞療法は、市場をCAR-T細胞療法とTCR療法にさらに細分化し、遺伝子工学と個別化医療の相互作用を強調しています。

細胞培養は2D培養システムと3D培養システム、細胞増殖は接着培養と懸濁培養、細胞分離は蛍光活性化細胞選別と磁気活性化細胞選別に分けられます。デリバリー方法に基づく分析では、生体外アプローチと生体内アプローチを区別し、アプリケーションによるセグメンテーションでは、心血管疾患、筋骨格系疾患、神経変性疾患、腫瘍学における市場機会を分類し、さらにサブカテゴリーを設けることで、ニュアンスの異なる概要を提供します。最後に、エンドユーザー別のセグメンテーションでは、バイオ製薬会社、病院（さらに非公開および公的セグメントに分析）、政府研究センターや大学を含む研究機関を網羅しています。これらの洞察は、各セグメント固有のニーズに対応する戦略を調整するための詳細なロードマップを提供し、その結果、目標とする成長と最適な資源配分を確実にします。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 患者の間でパーソナライズ医療ソリューションに関する認識と受容が高まっている
    • 世界中で慢性疾患および遺伝性疾患の有病率が増加
    • 研究開発への政府および民間資金による支援の増加
  • 抑制要因
    • 細胞治療技術に関連する高コスト
  • 機会
    • 細胞療法と医薬品のイノベーションを統合し、満たされていない医療ニーズに対応する
    • 細胞治療の革新に向けたバイオテクノロジー企業とヘルスケア機関の提携の拡大
  • 課題
    • 臨床試験への患者の募集と維持の難しさ
• 市場セグメンテーション分析
  • 治療の種類：免疫拒絶のリスクを最小限に抑えるための自己細胞療法の利用増加
  • 応用：血管新生を促進し、心筋組織を修復する心血管疾患における細胞治療技術の応用が増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 細胞治療技術市場：提供別

• 消耗品
• 装置
  • バイオリアクター
  • 細胞分析装置
• ソフトウェアとサービス
  • データ管理
  • 品質管理

第7章 細胞治療技術市場治療の種類別

• 同種細胞療法
  • 樹状細胞
  • 誘導多能性幹細胞
  • ナチュラルキラー細胞
• 自家細胞療法
  • 造血幹細胞
  • 間葉系幹細胞
  • T細胞
• 遺伝子組み換え細胞療法
  • CAR-T細胞療法
  • TCR（T細胞受容体）療法

第8章 細胞治療技術市場：製造工程別

• 細胞培養
  • 2D培養システム
  • 3D培養システム
• 細胞増殖
  • 固執する文化
  • 懸濁培養
• 細胞分離
  • 蛍光活性化細胞選別
  • 磁気活性化細胞選別

第9章 細胞治療技術市場：配送方法別

• 生体外
• In vivo

第10章 細胞治療技術市場：用途別

• 心血管疾患
  • 虚血性心疾患
  • 末梢動脈疾患
• 筋骨格系障害
  • 変形性関節症
  • 関節リウマチ
• 神経変性疾患
  • アルツハイマー病
  • パーキンソン病
• 腫瘍学
  • 血液がん
  • 固形腫瘍
    • 乳がん
    • 肺がん
    • 前立腺がん

第11章 細胞治療技術市場：エンドユーザー別

• バイオ医薬品企業
• 病院
  • 私立病院
  • 公立病院
• 調査機関
  • 政府研究センター
  • 大学の学術

第12章 南北アメリカの細胞治療技術市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域の細胞治療技術市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカの細胞治療技術市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Adaptimmune Limited
• Allogene Therapeutics Inc.
• Atara Biotherapeutics, Inc.
• Bellicum Pharmaceuticals, Inc.
• Bluebird Bio Inc.
• Cellectis SA
• Century Therapeutics, Inc.
• Charles River Laboratories International, Inc.
• ElevateBio LLC
• Gamida Cell Ltd.
• GE HealthCare Technologies Inc.
• Gilead Sciences, Inc.
• Iovance Biotherapeutics, Inc.
• Johnson & Johnson Services, Inc.
• Legend Biotech USA Inc.
• Novartis AG
• Sartorius AG
• STEMCELL Technologies Inc.
• Takara Bio Inc.
• Takeda Pharmaceutical Company Limited
• Thermo Fisher Scientific Inc.
• Vericel Corporation

LIST OF FIGURES

• FIGURE 1. CELL THERAPY TECHNOLOGIES MARKET MULTI-CURRENCY
• FIGURE 2. CELL THERAPY TECHNOLOGIES MARKET MULTI-LANGUAGE
• FIGURE 3. CELL THERAPY TECHNOLOGIES MARKET RESEARCH PROCESS
• FIGURE 4. CELL THERAPY TECHNOLOGIES MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 19. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 23. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 27. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 28. CELL THERAPY TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 29. CELL THERAPY TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. CELL THERAPY TECHNOLOGIES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CELL THERAPY TECHNOLOGIES MARKET DYNAMICS
• TABLE 7. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DATA MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY QUALITY CONTROL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NATURAL KILLER CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY T-CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CAR-T CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY TCR (T-CELL RECEPTOR) THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 2D CULTURE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 3D CULTURE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ADHERENT CULTURE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SUSPENSION CULTURE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY FLUORESCENCE-ACTIVATED CELL SORTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MAGNETIC-ACTIVATED CELL SORTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY REGION, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 51. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 52. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2030 (USD MILLION)
• TABLE 53. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 54. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 55. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 56. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 57. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 58. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 59. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 60. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 61. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 62. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOLOGICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 63. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 64. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 65. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 66. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 67. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
• TABLE 68. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 69. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 70. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 71. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 72. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 73. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 74. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 75. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 76. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 77. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY UNIVERSITY ACADEMICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 78. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 79. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 80. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 81. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
• TABLE 82. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 84. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 85. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 86. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 87. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
• TABLE 88. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2030 (USD MILLION)
• TABLE 89. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2030 (USD MILLION)
• TABLE 90. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 91. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2030 (USD MILLION)
• TABLE 93. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 94. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 95. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 96. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
• TABLE 97. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 98. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 99. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 100. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 101. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 102. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 103. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
• TABLE 104. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 106. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 107. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 108. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 109. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
• TABLE 110. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2030 (USD MILLION)
• TABLE 111. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2030 (USD MILLION)
• TABLE 112. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 113. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2030 (USD MILLION)
• TABLE 115. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 116. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 117. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 118. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
• TABLE 119. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 120. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 121. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 122. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 123. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 124. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
• TABLE 125. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 127. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 128. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 129. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 130. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
• TABLE 131. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2030 (USD MILLION)
• TABLE 132. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2030 (USD MILLION)
• TABLE 133. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 134. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2030 (USD MILLION)
• TABLE 136. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 137. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 138. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 139. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
• TABLE 140. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 141. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 142. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 143. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 144. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 145. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
• TABLE 146. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 148. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 149. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 150. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 151. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
• TABLE 152. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2030 (USD MILLION)
• TABLE 153. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2030 (USD MILLION)
• TABLE 154. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 155. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 156. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2030 (USD MILLION)
• TABLE 157. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 158. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 159. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 160. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
• TABLE 161. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 162. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 163. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 164. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 165. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 166. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
• TABLE 167. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 168. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 169. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 170. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 171. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 172. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
• TABLE 173. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2030 (USD MILLION)
• TABLE 174. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2030 (USD MILLION)
• TABLE 175. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 176. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 177. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2030 (USD MILLION)
• TABLE 178. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 179. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 180. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 181. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
• TABLE 182. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 183. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 184. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 185. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 186. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 187. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
• TABLE 188. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 189. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 190. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 191. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 192. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 193. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
• TABLE 194. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2030 (USD MILLION)
• TABLE 195. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2030 (USD MILLION)
• TABLE 196. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 197. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 198. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2030 (USD MILLION)
• TABLE 199. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 200. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 201. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 202. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
• TABLE 203. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 204. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 205. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 206. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 207. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 208. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 209. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
• TABLE 210. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 211. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 212. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 213. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 214. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 215. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
• TABLE 216. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2030 (USD MILLION)
• TABLE 217. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2030 (USD MILLION)
• TABLE 218. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 219. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 220. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2030 (USD MILLION)
• TABLE 221. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 222. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 223. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 224. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
• TABLE 225. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 226. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 227. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 228. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 229. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 230. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 231. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
• TABLE 232. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 233. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 234. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 235. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 236. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 237. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
• TABLE 238. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2030 (USD MILLION)
• TABLE 239. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2030 (USD MILLION)
• TABLE 240. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 241. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 242. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2030 (USD MILLION)
• TABLE 243. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 244. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 245. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 246. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
• TABLE 247. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 248. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 249. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 250. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 251. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 252. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
• TABLE 253. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 254. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 255. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 256. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 257. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 258. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
• TABLE 259. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2030 (USD MILLION)
• TABLE 260. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2030 (USD MILLION)
• TABLE 261. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 262. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 263. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2030 (USD MILLION)
• TABLE 264. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 265. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 266. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 267. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
• TABLE 268. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 269. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 270. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 271. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 272. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 273. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
• TABLE 274. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 275. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 276. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 277. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 278. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 279. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
• TABLE 280. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2030 (USD MILLION)
• TABLE 281. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2030 (USD MILLION)
• TABLE 282. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 283. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 284. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2030 (USD MILLION)
• TABLE 285. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 286. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 287. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 288. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
• TABLE 289. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 290. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 291. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 292. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 293. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 294. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
• TABLE 295. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 296. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 297. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 298. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2030 (USD MILLION)
• TABLE 299. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
• TABLE 300. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
• TABLE 301. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2030 (USD MILLION)
• TABLE 302. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2030 (USD MILLION)
• TABLE 303. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
• TABLE 304. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 305. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2030 (USD MILLION)
• TABLE 306. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2030 (USD MILLION)
• TABLE 307. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 308. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
• TABLE 309. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
• TABLE 310. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 311. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
• TABLE 312. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
• TABLE 313. JAPAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD

The Cell Therapy Technologies Market was valued at USD 4.66 billion in 2024 and is projected to grow to USD 5.29 billion in 2025, with a CAGR of 14.05%, reaching USD 10.25 billion by 2030.

The field of cell therapy technologies has rapidly emerged as a cornerstone of modern medical innovation, enabling transformative treatments in regenerative medicine and oncology. This market is witnessing an influx of groundbreaking scientific discoveries and a surge in investments that are redefining the boundaries of traditional therapeutic approaches. As industry stakeholders navigate increasingly complex regulatory environments and manage escalating patient expectations, the need for robust market insights has never been greater.

Recent advancements in laboratory techniques, manufacturing processes, and quality control methodologies have paved the way for the commercialization of novel cell-based treatments. Driven by both public and private sector investments, the ecosystem is evolving at a breakneck pace. This analytical overview encapsulates the innovative spirit of cell therapy technologies while providing a detailed examination of pivotal factors such as market segmentation, geographic trends, and leading industry players. The discussion that follows is designed to furnish decision-makers with a balanced, fact-based understanding of trends, opportunities, and challenges in this dynamic landscape.

Transformative Shifts Reshaping the Cell Therapy Technologies Landscape

In recent years, transformative shifts have redefined the cell therapy technologies landscape, driven by a confluence of scientific innovation, strategic investment, and evolving regulatory frameworks. Emerging technologies in bioprocessing and automation have revolutionized manufacturing, leading to improved efficiency and scalability. In addition, digital advancements are now playing a critical role in integrating data-driven insights with traditional lab-based approaches, thereby enabling more precise therapies and ensuring rigorous quality control.

Market dynamics are also reshaped by cross-disciplinary collaborations, with academic institutions and biopharmaceutical companies pooling resources and expertise to fast-track breakthroughs. Regulatory agencies across various regions have introduced forward-thinking policies that not only safeguard patient safety but also promote accelerated pathways to market. These progressive shifts are complemented by a growing consumer demand for therapies that are personalized and minimally invasive. Together, these factors signal an industry transitioning from experimental treatments to widely accessible, highly effective therapeutic solutions. The interplay between innovation, regulation, and market demand continues to sculpt the landscape, providing an environment ripe for disruptive growth and transformative potential.

Key Segmentation Insights in the Cell Therapy Technologies Market

An in-depth exploration of the market reveals critical segmentation dimensions that provide insights into the diverse categorizations within cell therapy technologies. When analyzed based on offering, the market is categorized into consumables, equipment, and software and services, where equipment itself is divided into bioreactors and cell analyzers, and software and services further bifurcate into data management and quality control. This layered segmentation underscores the multifaceted nature of supply chains and the integration of digital solutions with traditional hardware in driving market advancement.

Further segmentation by therapy type distinguishes between allogeneic cell therapy, autologous cell therapy, and gene-modified cell therapy. Detailed analysis shows that allogeneic cell therapy branches out into dendritic cells, induced pluripotent stem cells, and natural killer cells, while autologous cell therapy covers hematopoietic stem cells, mesenchymal stem cells, and T-cells. Gene-modified cell therapy refines the market further into CAR-T cell therapy and TCR therapy, highlighting the interplay between genetic engineering and personalized medicine.

Additional segmentation is observed in the manufacturing process, where distinctions are made across cell culture, cell expansion, and cell separation; cell culture is split into 2D and 3D culture systems, cell expansion into adherent and suspension cultures, and cell separation into fluorescence-activated cell sorting and magnetic-activated cell sorting. Analysis based on delivery method differentiates between ex vivo and in vivo approaches, and segmentation by application categorizes market opportunities in cardiovascular disease, musculoskeletal disorders, neurodegenerative diseases, and oncology, with further sub-categories providing a nuanced overview. Finally, segmentation by end user encompasses biopharmaceutical companies, hospitals - further analyzed into private and public segments - and research institutes, which include government research centers and universities. These insights offer a detailed roadmap for tailoring strategies that cater to the specific needs of each segment, thus ensuring targeted growth and optimized resource allocation.

Based on Offering, market is studied across Consumables, Equipment, and Software & Services. The Equipment is further studied across Bioreactors and Cell Analyzers. The Software & Services is further studied across Data Management and Quality Control.

Based on Therapy Type, market is studied across Allogeneic Cell Therapy, Autologous Cell Therapy, and Gene-Modified Cell Therapy. The Allogeneic Cell Therapy is further studied across Dendritic Cells, Induced Pluripotent Stem Cells, and Natural Killer Cells. The Autologous Cell Therapy is further studied across Hematopoietic Stem Cells, Mesenchymal Stem Cells, and T-Cells. The Gene-Modified Cell Therapy is further studied across CAR-T Cell Therapy and TCR (T-Cell Receptor) Therapy.

Based on Manufacturing Process, market is studied across Cell Culture, Cell Expansion, and Cell Separation. The Cell Culture is further studied across 2D Culture Systems and 3D Culture Systems. The Cell Expansion is further studied across Adherent Culture and Suspension Culture. The Cell Separation is further studied across Fluorescence-Activated Cell Sorting and Magnetic-Activated Cell Sorting.

Based on Delivery Method, market is studied across Ex vivo and In vivo.

Based on Application, market is studied across Cardiovascular Disease, Musculoskeletal Disorders, Neurodegenerative Diseases, and Oncology. The Cardiovascular Disease is further studied across Ischemic Heart Disease and Peripheral Artery Disease. The Musculoskeletal Disorders is further studied across Osteoarthritis and Rheumatoid Arthritis. The Neurodegenerative Diseases is further studied across Alzheimer's Disease and Parkinson's Disease. The Oncology is further studied across Hematological Cancer and Solid Tumors. The Solid Tumors is further studied across Breast Cancer, Lung Cancer, and Prostate Cancer.

Based on End User, market is studied across Biopharmaceutical Companies, Hospitals, and Research Institutes. The Hospitals is further studied across Private Hospitals and Public Hospitals. The Research Institutes is further studied across Government Research Centers and University Academics.

Key Regional Trends Driving Global Market Dynamics

The global cell therapy technologies market is experiencing region-specific trends that highlight diverse adoption patterns and investment priorities. In the Americas, there is a robust focus on capitalizing on fast-paced innovation alongside a well-established regulatory framework that supports rapid market entry and commercialization. Europe, the Middle East & Africa exhibit a blend of regulatory stringency and emerging market opportunities, with research and healthcare institutions driving early-stage clinical developments and technology integration. Meanwhile, the Asia-Pacific region has emerged as a fertile ground for scaling innovations, offering extensive support for research collaborations and a surge in infrastructure investments that facilitate local manufacturing and quality control advancements.

These regional insights reflect varied yet interconnected approaches to implementing cell therapy solutions across different healthcare ecosystems. By recognizing the strategic strengths of each region, stakeholders can better align their investment and operational strategies to tap into localized opportunities while balancing broader global trends. Careful consideration of these geographical factors is essential for optimizing market entry strategies and ensuring sustainable long-term growth.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insights on Leading Companies Shaping the Future of Cell Therapy Technologies

Several key players have emerged as frontrunners in the cell therapy technologies space, driving innovations that are reshaping the therapeutic landscape. Companies such as Adaptimmune Limited, Allogene Therapeutics Inc., and Atara Biotherapeutics, Inc. are at the forefront of developing pioneering treatments, leveraging advancements in cellular engineering and process optimization. Notably, Bellicum Pharmaceuticals, Inc. and Bluebird Bio Inc. have carved a niche with their focus on next-generation immunotherapies, while Cellectis SA and Century Therapeutics, Inc. are redefining manufacturing techniques to ensure scalability and clinical efficacy.

Other leading companies, including Charles River Laboratories International, Inc., ElevateBio LLC, and Gamida Cell Ltd., have been instrumental in providing comprehensive R&D and manufacturing support, thus facilitating innovative breakthroughs across the board. The integrated contributions of GE HealthCare Technologies Inc., Gilead Sciences, Inc., and Iovance Biotherapeutics, Inc. further highlight an established commitment to improving patient outcomes through state-of-the-art technologies. Moreover, industry giants such as Johnson & Johnson Services, Inc. and Legend Biotech USA Inc. continue to invest in clinical trials and strategic partnerships, while Novartis AG, Sartorius AG, and STEMCELL Technologies Inc. drive operational excellence through rigorous process improvements. The impactful endeavors of Takara Bio Inc., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., and Vericel Corporation collectively illustrate the sector's momentum toward transformative therapeutic solutions.

The report delves into recent significant developments in the Cell Therapy Technologies Market, highlighting leading vendors and their innovative profiles. These include Adaptimmune Limited, Allogene Therapeutics Inc., Atara Biotherapeutics, Inc., Bellicum Pharmaceuticals, Inc., Bluebird Bio Inc., Cellectis SA, Century Therapeutics, Inc., Charles River Laboratories International, Inc., ElevateBio LLC, Gamida Cell Ltd., GE HealthCare Technologies Inc., Gilead Sciences, Inc., Iovance Biotherapeutics, Inc., Johnson & Johnson Services, Inc., Legend Biotech USA Inc., Novartis AG, Sartorius AG, STEMCELL Technologies Inc., Takara Bio Inc., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., and Vericel Corporation. Actionable Recommendations for Industry Leaders in Cell Therapy Technologies

For decision-makers and strategists poised to capitalize on the evolving opportunities in the cell therapy technologies market, several actionable recommendations stand out. Firstly, leaders should prioritize investment in research and development initiatives that emphasize scalability and process optimization, ensuring that emerging trends in manufacturing and digital integration are fully leveraged. Embracing collaborative models that incorporate partnerships between technological innovators, therapeutic developers, and clinical researchers can further expedite product development and market entry.

It is also imperative to enhance regulatory compliance frameworks by staying current with evolving global standards, particularly those concerning quality control and data integrity. By instituting rigorous internal protocols and adopting state-of-the-art process monitoring systems, companies can mitigate risks and maintain competitive advantages in a rapidly evolving environment. Additionally, fostering strong regional partnerships is crucial; tailoring strategies to market-specific needs in areas such as the Americas, Europe, Middle East & Africa, and Asia-Pacific will drive targeted growth and better resource allocation.

Finally, building robust portfolios that align product offerings across consumables, equipment, and integrated software and services can help maximize value across end user populations. Industry leaders should consistently re-evaluate market segmentation insights to identify emerging niche opportunities and adjust investment priorities accordingly. A proactive, multi-dimensional approach is essential for harnessing the full potential of this transformative market.

Conclusion: Charting the Course for Future Innovation in Cell Therapy Technologies

In summary, the multifaceted nature of the cell therapy technologies market presents both unprecedented opportunities and complex challenges. From a comprehensive review of segmentation facets-including offerings, therapy types, manufacturing processes, delivery methods, and end-user applications-to a detailed examination of regional trends and key industry players, it is evident that the market is poised for significant transformation. By synthesizing insights drawn from diverse dimensions of technological innovation, regulatory evolution, and market dynamics, stakeholders can develop tailored strategies that capture incremental value and drive long-term growth.

As the industry continues to evolve, it is crucial for companies to remain agile and responsive to emerging trends, ensuring that their innovation pipelines and operational strategies are in sync with the rapidly changing landscape. The insights presented in this analysis provide a clear roadmap for navigating the complex interplay of challenges and opportunities, ultimately laying the foundation for a future characterized by enhanced therapeutic impact and improved patient outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing awareness and acceptance among patients regarding personalized medicine solutions
    • 5.1.1.2. Increasing prevalence of chronic and genetic disorders worldwide
    • 5.1.1.3. Rising government and private funding support for research and development initiatives
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with cell therapy technologies
  • 5.1.3. Opportunities
    • 5.1.3.1. Integrating cell therapies with pharmaceutical innovations to address unmet medical needs
    • 5.1.3.2. Growing partnerships between biotech companies and healthcare institutions for cell therapy innovations
  • 5.1.4. Challenges
    • 5.1.4.1. Difficulty in recruiting and retaining patients for clinical trials
• 5.2. Market Segmentation Analysis
  • 5.2.1. Therapy Type: Rising utilization of autologous cell therapy to minimize the risk of immune rejection
  • 5.2.2. Application: Rising application of cell therapy technologies in cardiovascular diseases to enhance angiogenesis and repair myocardial tissue
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cell Therapy Technologies Market, by Offering

• 6.1. Introduction
• 6.2. Consumables
• 6.3. Equipment
  • 6.3.1. Bioreactors
  • 6.3.2. Cell Analyzers
• 6.4. Software & Services
  • 6.4.1. Data Management
  • 6.4.2. Quality Control

7. Cell Therapy Technologies Market, by Therapy Type

• 7.1. Introduction
• 7.2. Allogeneic Cell Therapy
  • 7.2.1. Dendritic Cells
  • 7.2.2. Induced Pluripotent Stem Cells
  • 7.2.3. Natural Killer Cells
• 7.3. Autologous Cell Therapy
  • 7.3.1. Hematopoietic Stem Cells
  • 7.3.2. Mesenchymal Stem Cells
  • 7.3.3. T-Cells
• 7.4. Gene-Modified Cell Therapy
  • 7.4.1. CAR-T Cell Therapy
  • 7.4.2. TCR (T-Cell Receptor) Therapy

8. Cell Therapy Technologies Market, by Manufacturing Process

• 8.1. Introduction
• 8.2. Cell Culture
  • 8.2.1. 2D Culture Systems
  • 8.2.2. 3D Culture Systems
• 8.3. Cell Expansion
  • 8.3.1. Adherent Culture
  • 8.3.2. Suspension Culture
• 8.4. Cell Separation
  • 8.4.1. Fluorescence-Activated Cell Sorting
  • 8.4.2. Magnetic-Activated Cell Sorting

9. Cell Therapy Technologies Market, by Delivery Method

• 9.1. Introduction
• 9.2. Ex vivo
• 9.3. In vivo

10. Cell Therapy Technologies Market, by Application

• 10.1. Introduction
• 10.2. Cardiovascular Disease
  • 10.2.1. Ischemic Heart Disease
  • 10.2.2. Peripheral Artery Disease
• 10.3. Musculoskeletal Disorders
  • 10.3.1. Osteoarthritis
  • 10.3.2. Rheumatoid Arthritis
• 10.4. Neurodegenerative Diseases
  • 10.4.1. Alzheimer's Disease
  • 10.4.2. Parkinson's Disease
• 10.5. Oncology
  • 10.5.1. Hematological Cancer
  • 10.5.2. Solid Tumors
    • 10.5.2.1. Breast Cancer
    • 10.5.2.2. Lung Cancer
    • 10.5.2.3. Prostate Cancer

11. Cell Therapy Technologies Market, by End User

• 11.1. Introduction
• 11.2. Biopharmaceutical Companies
• 11.3. Hospitals
  • 11.3.1. Private Hospitals
  • 11.3.2. Public Hospitals
• 11.4. Research Institutes
  • 11.4.1. Government Research Centers
  • 11.4.2. University Academics

12. Americas Cell Therapy Technologies Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Cell Therapy Technologies Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Cell Therapy Technologies Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Evotec and Novo Nordisk collaborate to advance off-the-shelf cell therapies
  • 15.3.2. CPC launches Aseptic Connector for enhanced cell and gene therapy cryopreservation
  • 15.3.3. Cellular Origins acquires Actia Platform IP to boost automated cell therapy manufacturing
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Adaptimmune Limited
• 2. Allogene Therapeutics Inc.
• 3. Atara Biotherapeutics, Inc.
• 4. Bellicum Pharmaceuticals, Inc.
• 5. Bluebird Bio Inc.
• 6. Cellectis SA
• 7. Century Therapeutics, Inc.
• 8. Charles River Laboratories International, Inc.
• 9. ElevateBio LLC
• 10. Gamida Cell Ltd.
• 11. GE HealthCare Technologies Inc.
• 12. Gilead Sciences, Inc.
• 13. Iovance Biotherapeutics, Inc.
• 14. Johnson & Johnson Services, Inc.
• 15. Legend Biotech USA Inc.
• 16. Novartis AG
• 17. Sartorius AG
• 18. STEMCELL Technologies Inc.
• 19. Takara Bio Inc.
• 20. Takeda Pharmaceutical Company Limited
• 21. Thermo Fisher Scientific Inc.
• 22. Vericel Corporation